CASSS: Mass Spec 2024
Rockville, MD, USA
September 10–13, 2024
Did you miss Genedata at CASSS: Mass Spec 2024?
There's still time to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, and quality control of biologicals.
For a limited time only, download our posters featured at CASSS: Mass Spec 2024:
AI-based Denoising of LC-MS Data via Generative Adversarial Networks: A Proof of Concept
Daniel Siegismund1, Arnd Brandenburg1, Carsten Soenksen1, Aude Tartière2, Stefano Gotta1, Stephan Steigele1
1Genedata AG, Basel, Switzerland; 2Genedata Inc., San Francisco, CA, USA
An Automated, Sample-Specific Data Workflow for High-Throughput Identity Testing of Oligonucleotide Therapeutics
Catherine Evans1, Aude Tartière2, Stephen Kok2, Michelle English3, Annie Goodstein2, Arnd Brandenburg1
1Genedata AG, Basel, Switzerland; 2Genedata Inc., Boston, MA, USA
A Data Processing Workflow Combining Orthogonal MS/MS Fragmentation Data for Comprehensive Middle-down Analysis
Michelle English1, Aude Tartière2, Catherine Evans3, Stephen Kok2, Annie Goodstein2, Arnd Brandenburg3
1Genedata Inc., Boston, MA, USA; 2Genedata Inc., San Francisco, CA, USA; 3Genedata AG, Basel, Switzerland;
Automated and Robust Identification of Scrambled Disulfide Bonds in Biotherapeutics
Stephen Kok1, Michelle English2, Aude Tartière1, Catherine Evans3, Annie Goodstein1, Arnd Brandenburg3
1Genedata Inc., San Francisco, CA, USA; 2Genedata Inc., Boston, MA, USA; 3Genedata AG, Basel, Switzerland;
Access our CASSS: Mass Spec 2024 Webinar
Rapid MS-Based Profiling, Fingerprinting, and Speciation of Polymeric Excipients in Biotherapeutic Drug Products
Presenter: Ross Yang, Merck Sharp & Dohme, NJ, USA
Date/Time: Monday, September 9, 2024 I 4:00 PM - 5:00 PM CEST
Our Customers' Presentations at CASSS 2024
Intact Mass Characterization of Multi-Specific Therapeutic Antibodies
1Kalie Mix,
1Sanofi, Cambridge, MA, USA
High-throughput Screening Strategies to Characterize Protein Conjugation
1Anumita Saha
1Merck & Co., Inc., Rahway, NJ, USA
Streamlining Characterization Workflows for Biologics
1David Bush
1Novartis Institutes for BioMedical Research (NIBR) , Cambridge, MA, USA
Development of Novel Chromatographic and Mass Spectrometric Techniques for Characterizations of BsAbs and ADCs
1Fengfei Ma
1Merck & Co., Inc., San Francisco, CA, USA
Towards The Global Approval of MAM Testing Strategy
1Joseph J. Mulholland
1Johnson & Johnson Innovative Medicine, Malvern, PA, USA
Our Roundtable Discussions
September 12, 16:30 - 17:30
Table 1 - New Mass Spec Methods to Tackle New Biotherapeutic Challenges
Table 3 - Multi-Attribute Method (MAM) in Development vs. MAM in QC
Table 4 - Best Practices of Extended Characterization of Mass Spectrometry Methods
Table 9 - Best Practices for Predicting, Elucidating and Monitoring Hotspots by MS